CD19/CD22 chimeric antigen receptor T cell / Kecellitics Biotech - LARVOL DELTA

Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy for refractory or relapsed burkitt lymphoma (ASH 2025) - P=N/A | "The initial ASCTregimen was BEAM until 2022; it was then modified to Be+IDA+FLU+Ara-C+melphalan (BIFAM)...One month post-infusion of CAR-T cells,maintenance therapy with a CD20 monoclonal antibody and chidamide (an histone deacetylaseinhibitors, HDACi) was initiated.There were 9 males and 4 females, with a median age of 29 years (range: 4 to 44)...Subgroup analyses indicated that there were no significantdifferences in 2-year OS and PFS based on the presence of large masses versus their absence (57.1% vs.80%), bone marrow ±CNS involvement (53.3% vs. 71.4%), TP53 abnormalities (71.4% vs. 50%), bridgingtherapy with radiotherapy versus without it (71.4% vs. 53.3%), BEAM versus BIFAM regimens (66.7% vs.66.7%) (all p>0.05).ConclusionThis clinical trial confirmed the efficacy and safety of ASCT followed by CD19/CD22 CAR-T therapy for R/RBurkitt lymphoma, demonstrating a 2-year OS rate of 65.6% and a 2-year PFS rate of 56.3%...There were 9 males and 4 females,..."

IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Burkitt Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation • CD22 • TP53

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Kecellitics Biotech Company Ltd

CAR T-Cell Therapy • New P1/2 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD22